A dysglycaemic effect of statins in diabetes: relevance to clinical practice?

[1]  Hynek Pikhart,et al.  HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials , 2015, The Lancet.

[2]  A. Adler,et al.  Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis , 2014, Diabetologia.

[3]  Jennifer G. Robinson,et al.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[4]  Jbs Board.  Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3) , 2014, Heart.

[5]  N. Wong.  Faculty Opinions recommendation of 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014 .

[6]  Tom S. Price,et al.  Causal effects of body mass index on cardiometabolic traits and events: a Mendelian randomization analysis. , 2014, American journal of human genetics.

[7]  Tara Gomes,et al.  Risk of incident diabetes among patients treated with statins: population based study , 2013, BMJ.

[8]  S. de Servi,et al.  Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. , 2013, The American journal of cardiology.

[9]  N. Sattar,et al.  Revisiting the links between glycaemia, diabetes and cardiovascular disease , 2013, Diabetologia.

[10]  R. Collins,et al.  Statins for people at low risk of cardiovascular disease – Authors' reply , 2012, The Lancet.

[11]  R. Collins,et al.  The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials , 2012, The Lancet.

[12]  N. Sattar,et al.  Statins are diabetogenic--myth or reality? , 2012, Atherosclerosis. Supplements.

[13]  Salim Yusuf,et al.  Basal insulin and cardiovascular and other outcomes in dysglycemia. , 2012, The New England journal of medicine.

[14]  Paul Welsh,et al.  Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. , 2011, JAMA.

[15]  Vilmundur Gudnason,et al.  Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death , 2011 .

[16]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[17]  M. Gnant,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010 .

[18]  Yasuo Ohashi,et al.  Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials , 2010, The Lancet.

[19]  C. Pepine,et al.  Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum. , 2009, Journal of the American College of Cardiology.

[20]  R. Collins,et al.  Statins and diabetes – Authors' reply , 2008, The Lancet.

[21]  R Peto,et al.  Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. , 2008, Lancet.

[22]  J. Robson,et al.  Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease , 2007, Heart.

[23]  R. Holman,et al.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.

[24]  M. Hernán,et al.  An analysis of electronic medical records to evaluate possible bias due to differential survival , 2013 .